• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ELI LILLY AND COMPANY HUMAPEN LUXURA BURGUNDY FOR TREATMENT PURPOSES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ELI LILLY AND COMPANY HUMAPEN LUXURA BURGUNDY FOR TREATMENT PURPOSES Back to Search Results
Model Number MS9662
Device Problem Device Operates Differently Than Expected (2913)
Patient Problems Fever (1858); Hyperglycemia (1905); Unspecified Infection (1930); Occlusion (1984)
Event Type  Injury  
Manufacturer Narrative
This is an initial report. A follow-up report will be submitted when the final evaluation is completed.
 
Event Description
Lilly case id: (b)(6). This report is associated with product compliant: (b)(4). This solicited case, reported by a consumer via a patient support program (psp) and with additional information from initial reporter via psp, concerned a (b)(6) year-old (b)(6) male patient. Medical history included a cerebral infarction and a thigh amputation. Concomitant medications included metformin, acarbose, and an unspecified medication referred to as "jinqijiangtangpian", all for unspecified indications. The patient received insulin lispro (rdna origin) injections (humalog 100 u/ml) via reusable pen (humapen ergo ii), subcutaneously, (b)(4) units three times each day, for the treatment of diabetes mellitus starting in 2012. On an unspecified date, he had legs arterial occlusion. He underwent an unspecified legs suture surgery as corrective treatment. Also on an unspecified date, he experienced blood glucose increased and fever, and because of those events he was hospitalized on (b)(6) 2016. Further information regarding laboratory tests findings was not provided. The cause of fever was diagnosed as a leg infection, with his highest body temperature recorded at 39 to 40 degrees celsius. By (b)(6) 2016 he continued hospitalized. On an unspecified date, there was a product complaint against the humapen ergo ii (pc: (b)(4); lot number: 1201d06). By (b)(6) 2016, the events of leg infection and leg arterial occlusion were recovering. The outcome of the remaining events was not reported. Insulin lispro treatment was continued. The user of the device and his/ her training status was not provided. The device model duration of use and the suspect device duration of use were not reported. The action taken with the suspect device was not provided. If device is returned, evaluation will be performed to determine if a malfunction has occurred. The reporting consumer did not know if the events of leg infection and blood glucose increased were related to the insulin lispro and did not provide an assessment of relatedness regarding the remaining events. No follow-up would be pursued as the reporter refused to be contacted and treating physician contact details were not provided. Update 10-nov-2016: upon review, this case was opened to update the medwatch and european and canadian required device reporting elements for regulatory requirements. The product complaint information was added to the case. Update 18-nov-2016: additional information received on 16-nov-2016 and on 18-nov-2016 from initial reporter via psp were processed at the same time. Recoded the event of fever to leg infection and added new non-serious event of leg arterial occlusion. Narrative was updated accordingly. Upon review of initial information, coded metformin and acarbose as concomitant medications.
 
Manufacturer Narrative
No further follow up is planned. Evaluation summary: a male patient reported the injection button of his humapen luxura device could not be pushed down completely when injecting. The patient experienced increased blood glucose levels. The investigation of the returned device (batch 1201d06, manufactured january 2012) found the device met functional requirements and met dose accuracy and glide (injection) force specifications. No malfunction was identified. There is no evidence of improper use or storage.
 
Event Description
(b)(4). This solicited case, reported by a consumer via a patient support program (psp) and with additional information from the affiliate and the initial reporter via psp, concerned a (b)(6) asian male patient. Medical history included a cerebral infarction and a thigh amputation. Concomitant medications included metformin, acarbose, and an unspecified medication referred to as jinqijiangtangpian, all for unspecified indications. The patient received insulin lispro (rdna origin) injections (humalog 100 u/ml) via reusable pen (humapen luxura burgundy), subcutaneously, 14 units three times each day, for the treatment of diabetes mellitus starting in 2012. On an unspecified date, he had legs arterial occlusion. He underwent an unspecified legs suture surgery as corrective treatment. Also on an unspecified date, he experienced blood glucose increased and fever, and because of those events he was hospitalized on (b)(6) 2016. Further information regarding laboratory tests findings was not provided. The cause of fever was diagnosed as a leg infection, with his highest body temperature recorded at 39 to 40 degrees celsius. By (b)(6) 2016 he continued hospitalized. On an unspecified date, there was a product complaint against the luxura burgundy (product complaint (b)(4); lot number: 1201b06). By (b)(6) 2016, the events of leg infection and leg arterial occlusion were recovering. The outcome of the remaining events was not reported. Insulin lispro treatment was continued. The user of the device and his/ her training status was not provided. The device model duration of use and the suspect device duration of use were not reported. The device was returned on 02dec2016, and no malfunction was found. The reporting consumer did not know if the events of leg infection and blood glucose increased were related to the insulin lispro and did not provide an assessment of relatedness regarding the remaining events. No follow-up would be pursued as the reporter refused to be contacted and treating physician contact details were not provided. Update 10-nov-2016: upon review, this case was opened to update the medwatch and european and canadian required device reporting elements for regulatory requirements. The product complaint information was added to the case. Update 18-nov-2016: additional information received on 16-nov-2016 and on 18-nov-2016 from initial reporter via psp were processed at the same time. Recoded the event of fever to leg infection and added new non-serious event of leg arterial occlusion. Narrative was updated accordingly. Upon review of initial information, coded metformin and acarbose as concomitant medications. Update 02-dec-2016: additional information received on 02-dec-2016 from global product complaint database updated the lot number from 1201d06 to 1201b06 for product complaint (b)(4) which updated the device to a humapen luxura burgundy. The return date of the device was added, and the european and canadian required device reporting elements were updated. The product tab for humapen and the narrative were updated. Update 16-dec-2016: additional information received on 09nov2016 from affiliate. Product complaint reference number was received however it was already processed and present in narrative. No new adverse event information was received. Update 21dec2016: additional information received on 21dec2016 from the global product complaint database added the device specific safety summary and manufactured date of the device; updated the malfunction field to no; updated the medwatch and european and canadian required device reporting elements; and updated the narrative.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameHUMAPEN LUXURA BURGUNDY
Type of DeviceFOR TREATMENT PURPOSES
Manufacturer (Section D)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer (Section G)
PHILLIPS-MEDISIZE CORPORATION
415 red cedar street
medical device manufacturing
menomonie WI 54751
Manufacturer Contact
caroline rosewell
lilly corporate center
indianapolis, IN 46285
3172764376
MDR Report Key6124575
MDR Text Key60794847
Report Number1819470-2016-00298
Device Sequence Number1
Product Code FMF
Combination Product (y/n)N
PMA/PMN Number
K142518
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,consum
Type of Report Initial,Followup
Report Date 01/13/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/23/2016
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Other
Device Model NumberMS9662
Device Lot Number1201B06
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer12/02/2016
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received12/21/2016
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured01/31/2012
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 11/23/2016 Patient Sequence Number: 1
Treatment
ACARBOSE; INSULIN LISPRO; METFORMIN
-
-